What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study.

Sara PizzamiglioGiulia CosentinoChiara M CiniselliLoris De CeccoAlessandra CataldoIlaria PlantamuraTiziana TriulziSarra El-AbedYingbo WangMohammed BajjiPaolo NuciforoJens HuoberSusan L EllardDavid L RimmAndrea GombosMaria Grazia DaidonePaolo VerderioElda TagliabueSerena Di Cosimo Marilena V Iorio

Published in: Cancer medicine (2021)

Analyses of primary tumor tissue miRNAs hold the potential of a parsimonious tool to identify patients with differential clinical outcomes after trastuzumab based neoadjuvant therapy.

Keyphrases

positive breast cancer
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
lymph node
prognostic factors
peritoneal dialysis
squamous cell carcinoma
stem cells
epidermal growth factor receptor
risk assessment
mesenchymal stem cells
metastatic breast cancer
patient reported